Intranasal antibody prophylaxis for protection against viral disease

Clinical Microbiology Reviews

Volumn 12, Issue 3, 1999, Pages 383-393

  Weltzin, Richard ^a   Monath, Thomas P ^a  

^a Acambis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DRUG DELIVERY SYSTEM; HUMAN; INFLUENZA; INFLUENZA VIRUS; INTRANASAL DRUG ADMINISTRATION; NOSE MUCOSA; PARAINFLUENZA VIRUS 1; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA VIRUS INFECTION; UPPER RESPIRATORY TRACT INFECTION;

ANIMALIA; BACTERIA (MICROORGANISMS); HUMAN PARAINFLUENZA VIRUS 1; INFLUENZA VIRUS; RESPIRATORY SYNCYTIAL VIRUS; RNA VIRUSES; SYNCYTIAL VIRUS;

EID: 0032771060     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.12.3.383     Document Type: Article

References (116)

1. Agius, G., G. Dindinaud, R. J. Biggar, R. Peyre, V. Vaillant, S. Ranger, J. Y. Poupet, M. F. Cisse, and M. Castets. 1990. An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings. J. Med. Virol. 30:117-127.
2. Akerfeldt, S., S. Geijer, E. Holubars, G. Fuchs, and M. Brundin. 1972. Prophylactic and therapeutic antiviral effect of human gamma globulin. Biochem. Pharmacol. 21:503-509.
3. Akerfeldt, S., E. Lofberg, and G. Fuchs. 1973. Antiviral effect of human gamma globulin in mice. Comparison between the efficacy of local and systemic administration. Biochem. Pharmacol. 22:2911-2917.
4. Alwan, W. H., W. J. Kozlowska, and P. J. Openshaw. 1994. Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179:81-89.
5. Bansal, G. P., J. Hatfield, J. F. Young, F. H. Top, G. A. Prince, R. L. Horswood, V. Hemming, and S. Hensen. 1991. Efficacy of passively administered monoclonal antibodies against respiratory syncytial virus infection in cotton rats. Vaccines 91:283-288.
6. Beeler, J. A., and K. van Wyke Coelingh. 1989. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 63:2941-2950.
7. Bell, D. Y., J. A. Haseman, A. Spock, G. McLennan, and G. E. R. Hook. 1981. Plasma proteins of the bronchoalveolar surface of the lungs of smokers and nonsmokers. Am. Rev. Respir. Dis. 124:72-79.
8. Bienenstock, J., and D. Befus. 1984. Gut-and bronchus-associated lymphoid tissue. Am. J. Anat. 170:437-445.
9. Bockman, D. E., and M. D. Cooper. 1973. Pinocytosis by epithelium associated with lymphoid follicles in the bursa of Fabricius, appendix and Peyer's patches. An electron microscopic study. Am. J. Anat. 136:455-477.
10. Borrebaeck, C. A. K. 1992. Antibody engineering. A practical guide. W. H. Freeman & Co., New York, N.Y.
11. Bourgeois, C., J. B. Bour, L. S. Aho, and P. Pothier. 1998. Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J. Virol. 72:807-810.
12. Braley, J. F., C. A. Dawson, and V. L. Moore. 1978. Immunologic block against antigen absorption from isolated perfused rabbit lungs. J. Immunol. 121:926-929.
13. Brandtzaeg, P. 1984. Immune functions of human nasal mucosa and tonsils in health and disease, p. 28-95. In J. Bienenstock (ed.), Immunology of the lung and upper respiratory tract. McGraw-Hill Book Co., New York, N.Y.
14. Brandtzaeg, P. 1985. Role of J chain and secretory component in receptor-mediated glandular and hepatic transport of immunoglobulins in man. Scand. J. Immunol. 22:111-146.
15. Brown, W. R., R. W. Newcomb, and K. Ishizaka. 1970. Proteolytic degradation of exocrine and serum immunoglobulins. J. Clin. Investig. 49:1374-1380.
16. Burns, J. W., M. Siadat-Pajouh, A. A. Krishnaney, and H. B. Greenberg. 1996. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272:104-107.
17. Buthala, D. A., R. Damiano, and E. E. Eidson. 1970. Studies on coxsackie A-21 (COE) virus-infected volunteers: effect of local therapy with gamma globulin. Ann. N. Y. Acad. Sci. 173:794-807.
18. Cohen, A. B., and W. M. Gold. 1975. Defence mechanisms of the lungs. Annu. Rev. Physiol. 37:325-350.
19. Collins, P. L., R. M. Chanock, and K. McIntosh. 1996. Parainfluenza viruses, p. 1205-1241. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.). Virology. Lippincott-Raven Publishers, Philadelphia, Pa.
20. Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus, p. 1313-1351. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology. Lippincott-Raven Publishers, Philadelphia, Pa.
21. Colonno, R. J., P. L. Callahan, and W. J. Long. 1986. Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses. J. Virol. 57:7-12.
22. Colonno, R. J., J. E. Tomassini, and P. L. Callahan. 1987. Isolation and characterization of a monoclonal antibody which blocks attachment of human rhinoviruses, p. 93-102. In M. Brinton and R. Rueckert (ed.), Positive strand RNA viruses. Alan R. Liss, Inc., New York, N.Y.
23. Connors, M., N. A. Giese, A. B. Kulkarni, C.-Y. Firestone, H. C. Morse, and B. R. Murphy. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:5321-5325.
24. Couch, R. B. 1996. Rhinoviruses, p. 713-734. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology. Lippincott-Raven Publishers, Philadelphia, Pa.
25. Crowe, J. E., B. R. Murphy, R. M. Chanock, R. A. Williamson, C. F. Barbas, and D. R. Burton. 1994. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc. Natl. Acad. Sci. USA 91:1386-1390.
26. Englund, J. A., C. J. Sullivan, M. C. Jordan, L. P. Dehner, G. M. Vercellotti, and H. H. Balfour. 1988. Respiratory syncytial virus infection in immunocompromised adults. Ann. Intern. Med. 109:203-208.
27. Fruchtman, M. H., A. A. Mauceri, F. M. Wigley, and R. H. Waldman. 1972. Aerosol administration of human gamma globulin as prophylaxis against influenza virus challenge. Clin. Med. 79:17-20.
28. Giraudi, V., C. Riganti, M. R. Torales, H. Sedola, and E. Gaddi. 1997. Upper respiratory infections in children: response to endonasal administration of IGA. Int. J. Pediatr. Otorhinolaryngol. 39:103-110.
29. Graham, B. S., T. H. Davis, Y.-W. Tang, and W. C. Gruber. 1993. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with respiratory syncytial virus-specific immune serum. Pediatr. Res. 34:167-172.
30. Graham, B. S., G. S. Henderson, Y.-W. Tang, X. Lu, K. M. Neuzil, and D. G. Colley. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:2032-2040.
31. Graham, B. S., Y.-W. Tang, and W. C. Gruber. 1995. Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin. J. Infect. Dis. 171:1468-1474.
32. Gronthuis, J. R., E. A. F. Simoes, M. J. Levin, C. B. Hall, C. E. Long, W. J. Rodriguez, J. Arrobio, H. C. Meissner, D. R. Fulton, R. C. Welliver, D. A. Tristram, G. R. Siber, G. A. Prince, M. Van Raden, and V. G. Hemming. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N. Engl. J. Med. 329:1524-1530.
33. Hall, C. B., E. E. Walsh, C. E. Long, and K. C. Schnabel. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163:693-698.
34. Hammarstrom, L., A. Gardulf, V. Hammarstrom, A. Jannson, K. Lindberg, and C. I. E. Smith. 1994. Systemic and topical immunoglobulin treatment in immunocompromised patients. Immunol. Rev. 139:43-70.
35. Hammarstrom, L., and C. I. E. Smith. 1990. The use of intravenous IgG as prophylaxis and for treatment of infections. Infection 18:314-324.
36. Hayden, F. G., J. M. Gwaltney, and R. J. Colonno. 1988. Modification of experimental rhinovirus colds by receptor blockade. Antiviral Res. 9:233-247.
37. Heikkinen, T., A. Ruohola, O. Ruuskanen, M. Waris, M. Uhari, and L. Hammarstrom. 1998. Intranasally administered immunoglobulin for the prevention of rhinitis in children. Pediatr. Infect. Dis. J. 17:367-372.
38. Heilman, C. A. 1990. Respiratory syncytial and parainfluenza viruses. J. Infect. Dis. 161:402-406.
39. Hemming, V. G., G. A. Prince, J. R. Groothuis, and G. R. Siber. 1995. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin. Microbiol. Rev. 8:22-33.
40. Hemming, V. G., W. Rodriguez, H. W. Kim, C. D. Brandt, R. H. Parrott, B. Burch, G. A. Prince, P. A. Baron, R. J. Fink, and G. Reaman. 1987. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob. Agents Chemother. 31: 1882-1886.
41. Hemmingsson, P., and L. Hammarstrom. 1993. Nasal administration of immunoglobulin as effective prophylaxis against infections in elite cross-country skiers. Scand. J. Infect. Dis. 25:783-785.
42. Hirabayashi, Y., H. Kurata, H. Funato, T. Nagamine, C. Aizawa, S. Tamura, K. Shimada, and T. Kurata. 1990. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 8:243-248.
43. Huguenel, E. D., D. Cohn, D. P. Dockum, J. M. Greve, M. A. Fournel, L. Hammond, R. Irwin, J. Mahoney, A. McClelland, E. Muchmore, A. C. Ohlin, and P. Scuderi. 1997. Prevention of rhinovirus infection in chimpanzees by soluble intercellular adhesion molecule-1. Am. J. Respir. Crit. Care Med. 155:1206-1210.
44. IMpact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531-537.
45. Johnson, S., C. Oliver, G. A. Prince, V. G. Hemming, D. S. Pfarr, S.-C. Wang, M. Dormitzer, J. O'Grady, S. Koenig, J. K. Tamura, R. Woods, G. Bansal, D. Couchenour, E. Tsao, W. C. Hall, and J. K. Young. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224.
46. Kapikian, A. Z., R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:405-421.
47. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
48. Krause, R. M., N. J. Dimmock, and D. M. Morens. 1997. Summary of antibody workshop: the role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases. J. Infect. Dis. 176: 549-559.
49. Kuper, C. F., P. J. Koornstra, D. M. H. Hameleers, J. Biewenga, B. J. Spit, A. M. Duijvestijn, P. J. C. van Breda Vriesman, and T. Sminia. 1992. The role of nasopharyngeal lymphoid tissue. Immunol. Today 13:219-224.
50. Langman, J. M., and R. Rowland. 1986. The number and distribution of lymphoid follicles in the human large intestine. J. Anat. 149:189-194.
51. Liew, F. Y., S. M. Russell, G. Appleyard, C. M. Brand, and J. Beale. 1984. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cylotoxic T cell reactivity. Eur. J. Immunol. 14:350-356.
52. Lindberg, K., and B. Berglund. 1996. Effect of treatment with nasal IgA on the incidence of infectious disease in world-class canoeists. Int. J. Sports Med. 17:235-238.
53. Lorin, M. I., P. F. Gaerlan, and I. D. Mandel. 1972. Quantitative composition of nasal secretions in normal subjects. J. Lab. Clin. Med. 80:275-281.
54. Marlin, S. D., D. E. Staunton, T. A. Springer, C. Stratowa, W. Sommergruber, and V. J. Merluzzi. 1990. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature 344:70-72.
55. Mayrhofer, G. 1994. Epithelial disposition of antigen, p. 19-70. In R. Goldie (ed.), Immunopharmacology of epithelial barriers. Academic Press, Inc., London, United Kingdom.
56. Mazanec, M. B., C. L. Coudret, and D. R. Fletcher. 1995. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J. Virol. 69:1339-1343.
57. Mazanec, M. B., C. S. Kaetzel, M. E. Lamm, D. Fletcher, and J. G. Nedrud. 1992. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc. Natl. Acad. Sci. USA 89:6901-6905.
58. Mazanec, M. B., M. E. Lamm, D. Lyn, A. Portner, and J. G. Nedrud. 1992. Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. Virus Res. 23:1-12.
59. Mazanec, M. B., J. G. Nedrud, and M. E. Lamm. 1987. Immunoglobulin A monoclonal antibodies protect against Sendai virus. J. Virol. 61:2624-2626.
60. McGhee, J. R., and H. Kiyono. 1993. New perspectives in vaccine development: mucosal immunity to infections. Infect. Agents Dis. 2:55-73.
61. McIntosh, K., P. Halonen, and O. Ruuskanen. 1993. Report of a workshop on respiratory viral infections: epidemiology, diagnosis, treatment, and prevention. Clin. Infect. Dis. 16:151-164.
62. McIntosh, K., H. B. Masters, I. Orr, R. K. Chao, and R. M. Barkin. 1978. The immunologic response to infection with respiratory syncytial virus in infants. J. Infect. Dis. 138:24-32.
63. McNabb, P. C., and T. B. Tomasi. 1981. Host defense mechanisms at mucosal surfaces. Annu. Rev. Microbiol. 35:477-496.
64. Meissner, H. C. 1994. Economic impact of viral respiratory disease in children. J. Pediatr. 124:S17-S21.
65. Meissner, H. C., P. M. Schlievert, and D. Y. M. Leung. 1994. Mechanisms of immunoglobulin action: observations on Kawasaki syndrome and RSV prophylaxis. Immunol. Rev. 139:109-123.
66. Mestecky, J., and J. R. McGhee. 1987. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv. Immunol. 40:153-245.
67. Mestecky, J., J. R. McGhee, and C. O. Elson. 1988. Intestinal IgA system. Immunol. Allergy Clin. North Am. 8:349-368.
68. Mills, J., J. E. Van Kirk, P. F. Wright, and R. M. Chanock. 1971. Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J. Immunol. 107:123-130.
69. Murphy, B. R., and R. G. Webster. 1996. Orthomyxoviruses, p. 1397-1445. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology. Lippincott-Raven Publishers, Philadelphia, Pa.
70. Nader, P. R., M. S. Horwitz, and J. Rousseau. 1968. Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine. J. Pediatr. 72:22-28.
71. Neutra, M. R., and J.-P. Kraehenbuhl. 1992. Transepithelial transport and mucosal defence. I. The role of M cells. Trends Cell Biol. 2:134-138.
72. Newcomb, R. W., and C. A. Sutoris. 1974. Comparative studies on human and rabbit exocrine IgA antibodies to an albumin. Immunochemistry 111: 623-632.
73. Outlaw, M. C., and N. J. Dimmock. 1990. Mechanisms of neutralization of influenza virus on mouse tracheal epithelial cells by mouse monoclonal polymeric IgA and polyclonal IgM directed against the viral haemagglutinin. J. Gen. Virol. 71:69-76.
74. Owen, R. L., A. J. Piazza, and T. H. Ermak. 1991. Ultrastructural and cytoarchitectural features of lymphoreticular organs in the colon and rectum of adult BALB/c mice. Am. J. Anat. 190:10-18.
75. Parrott, R. H., H. W. Kim, J. O. Arrobio, D. S. Hodes, B. R. Murphy, C. D. Brandt, E. Camargo, and R. M. Chanock. 1973. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am. J. Epidemiol. 98:289-300.
76. Pedersen, H., and N. Mygind. 1976. Absence of axonemal arms in nasal mucosa cilia in Kartagener's syndrome. Nature 262:494-495.
77. PREVENT Study Group. 1997. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99:93-99.
78. Prince, G. A., V. G. Hemming, R. L. Horswood, P. A. Baron, and R. M. Chanock. 1987. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J. Virol. 61:1851-1854.
79. Prince, G. A., V. G. Hemming, R. L. Horswood, P. A. Baron, B. R. Murphy, and R. M. Chanock. 1990. Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection of cotton rats. J. Virol. 64:3091-3092.
80. Prince, G. A., V. G. Hemming, R. L. Horswood, and R. M. Chanock. 1985. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res. 3:193-206.
81. Prince, G. A., R. L. Horswood, E. Camargo, D. Koenig, and R. M. Chanock. 1983. Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infect. Immun. 42:81-87.
82. Prince, G. A., R. L. Horswood, and R. M. Chanock. 1985. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J. Virol. 55:517-520.
83. Prince, G. A., and D. D. Porter. 1996. Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. J. Infect. Dis. 173:598-608.
84. Proctor, D. F., and G. Lundqvist. 1973. Clearance of inhaled particles from the human nose. Arch. Intern. Med 131:132-139.
85. Ramisse, F., F. X. Derumoudt, M. Szatanik, A. Bianchi, P. Binder, C. Hannoun, and J. M. Alonso. 1998. Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab′)2 fragments. Clin. Exp. Immunol. 111:583-587.
86. Renegar, K. B., and P. A. Small. 1991. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. J. Virol. 65:2146-2148.
87. Renegar, K. B., and P. A. Small. 1991. Passive transfer of local immunity to influenza virus infection by IgA antibody. J. Immunol. 146:1972-1978.
88. Rimensberger, P. C., and U. B. Schaad. 1994. Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr. Infect. Dis. J. 13:328-330.
89. Roberts, S. R., R. W. Compans, and G. W. Wertz. 1995. Respiratory syncytial virus matures at the apical surface of polarized epithelial cells. J. Virol. 69:2667-2673.
90. Rodriguez, W. J., W. C. Gruber, J. R. Groothuis, E. A. Simoes, A. J. Rosas, M. Lepow, A. Kramer, and V. Hemming. 1997. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 100:937-942.
91. Rodriguez, W. J., W. C. Gruber, R. C. Welliver, J. R. Groothuis, E. A. F. Simoes, H. C. Meissner, V. G. Hemming, C. B. Hall, M. L. Lepow, A. J. Rosas, C. Robertsen, A. A. Kramer and the Respiratory Syncytial Virus Immune Globulin Study Group. 1997. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections. Pediatrics 99:454-461.
92. Rossen, R. D., A. L. Schade, W. T. Butler, and J. A. Kasel. 1966. The proteins in nasal secretion: a longitudinal study of the gammaA-globulin, gammaG-globulin, albumin, siderophilin, and total protein concentrations in nasal washings from adult male volunteers. J. Clin. Investig. 45:768-776.
93. Sami, I. R., F. M. Piazza, S. A. Johnson, M. E. R. Darnell, M. G. Ottolini, V. G. Hemming, and G. A. Prince. 1995. Systemic immunoprophylaxis of nasal respiratory syncytial virus infection in cotton rats. J. Infect. Dis. 171:440-443.
94. Siber, G. R., D. Leombruno, J. Leszczynski, J. McIver, D. Bodkin, R. Gonin, C. M. Thompson, E. E. Walsh, P. A. Piedra, V. G. Hemming, and G. A. Prince. 1994. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J. Infect. Dis. 169:1368-1373.
95. Siber, G. R., J. Leszczynski, V. Pena-Cruz, C. Ferren-Gardner, R. Anderson, V. G. Hemming, E. E. Walsh, J. Burns, K. McIntosh, R. Gonin, and L. J. Anderson. 1992. Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J. Infect. Dis. 165:456-463.
96. Smith, C. B., R. H. Purcell, J. A. Bellanti, and R. M. Chanock. 1966. Protective effect of antibody to parainfluenza type I virus. N. Engl. J. Med. 275:1145-1152.
97. Snell, N. J. C. 1997. New developments in the treatment of viral respiratory tract infections. Exp. Opin. Investig. Drugs 6:1001-1008.
98. Solari, R., and J.-P. Kraehenbuhl. 1985. The biosynthesis of secretory component and its role in the transepithelial transport of IgA dimer. Immunol. Today 6:17-20.
99. Spit, B. J., E. G. J. Hendriksen, J. P. Bruijntes, and C. F. Kuper. 1989. Nasal lymphoid tissue in the rat. Cell Tissue Res. 255:193-198.
100. Subramanian, K. N., L. E. Weisman, T. Rhodes, R. Ariagno, P. J. Sanchez, J. Steichen, L. B. Givner, T. L. Jennings, F. H. Top, D. Carlin, and E. Connor. 1998. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 17:110-115.
101. Tamura, S., H. Funato, Y. Hirabayashi, Y. Suzuki, T. Nagamine, C. Aizawa, and T. Kurata. 1991. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur. J. Immunol. 21:1337-1344.
102. Taylor, G., E. J. Stott, M. Bew, B. F. Fernie, P. J. Cote, A. P. Collins, M. Hughes, and J. Jebbett. 1984. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52:137-142.
103. Taylor, H. P., and N. J. Dimmock. 1985. Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. J. Exp. Med. 161:198-209.
104. Tempest, P. R., P. Bremner, M. Lambert, G. Taylor, J. M. Furze, F. J. Carr, and W. J. Harris. 1991. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Bio/Technology 9:266-271.
105. Tomasi, T. B., and H. M. Grey. 1972. Structure and function of immunoglobulin A. Prog. Allergy 16:81-213.
106. Underdown, B. J., and K. J. Dorrington. 1974. Studies on the structural and conformational basis for the relative resistance of serum and secretory immunoglobulin A to proteolysis. J. Immunol. 112:949-959.
107. Walker, R. I. 1994. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 12:387-400.
108. Walsh, E. E., J. J. Schlesinger, and M. W. Brandriss. 1984. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect. Immun. 43:756-758.
109. Waris, M. E., C. Tsou, D. D. Erdman, S. R. Zaki, and L. J. Anderson. 1996. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a Th2-like cytokine pattern. J. Virol. 70:2852-2860.
110. Watt, P. J., B. S. Robinson, C. R. Pringle, and D. A. J. Tyrrell. 1990. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine 8:231-236.
111. Weltzin, R., S. A. Hsu, E. S. Mittler, K. Georgakopoulos, and T. P. Monath. 1994. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob. Agents Chemother. 38:2785-2791.
112. Weltzin, R., H. Kleanthous, F. Guirakhoo, T. P. Monath, and C. K. Lee. 1997. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 15: 370-376.
113. Weltzin, R., P. Lucia-Jandris, P. Michetti, B. N. Fields, J. P. Kraehenbuhl, and M. R. Neutra. 1989. Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins. J. Cell Biol. 108:1673-1685.
114. Weltzin, R., V. Traina-Dorge, K. Soike, J. Y. Zhang, P. Mack, G. Soman, G. Drabik, and T. P. Monath. 1996. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J. Infect. Dis. 174:256-261.
115. Wong, J. P., L. L. Stadnyk, and E. G. Saravolac. 1994. Enhanced protection against respiratory influenza A infection in mice by liposome-encapsulated antibody. Immunology 81:280-284.
116. Wyde, P. R., D. K. Moore, T. Hepburn, C. L. Silverman, T. G. Porter, M. Gross, G. Taylor, S. G. Demuth, and S. B. Dillon. 1995. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatr. Res. 38:543-550.